Cannabis business leads today’s brief, with the industry’s most consequential takeover contest becoming increasingly public and contentious. Federal research infrastructure and a major California media antitrust battle round out the developments business readers should track.
Aurora and Curaleaf Escalate Hostile Takeover Battle
Aurora Cannabis and Curaleaf Holdings exchanged sharply worded statements Monday as Curaleaf continued its unsolicited effort to acquire Aurora. The offer provides 0.3463 of a Curaleaf subordinate voting share plus $0.75 in cash for each Aurora share, representing an implied value of approximately $4 per share when announced.
Aurora told shareholders to take no action while its board and special committee review the proposal. The medical cannabis producer argued that Curaleaf is undervaluing its international operations, EU-GMP production infrastructure and recent growth, including a reported 17% year-over-year increase in international net revenue.
Curaleaf responded that the companies have not held a substantive discussion about a transaction and criticized Aurora’s financial performance and use of selected operating metrics. Curaleaf said it remains willing to meet, while Aurora has not yet issued a formal board recommendation on the offer.
Why It Matters: Analysis: The dispute is becoming a test of how investors value international medical cannabis assets as the sector consolidates. A successful transaction would combine Curaleaf’s broader consumer platform with Aurora’s regulated medical operations and European manufacturing footprint; continued resistance could force Curaleaf to improve its terms, withdraw or pursue a prolonged shareholder campaign.
Source: Curaleaf Holdings
DEA Reviews California Company’s Cannabis Import and Manufacturing Applications
The Drug Enforcement Administration is considering separate applications from Castroville, California-based Biopharmaceutical Research Company to import cannabis materials and manufacture pharmaceutical-grade marijuana for federally compliant research.
The proposed import registration would cover flowering plants and cannabis derivatives intended for analytical chemistry, research and the production of dosage forms for preclinical and clinical trials. It would not authorize the importation of finished pharmaceutical products for commercial sale.
A second application seeks bulk-manufacturer registration for marijuana, marijuana extract and tetrahydrocannabinols. The notices initiate regulatory review rather than granting approval, and eligible registered parties may submit objections or request hearings following publication in the Federal Register.
Why It Matters: Analysis: Expanded federally authorized supply and manufacturing capacity could reduce longstanding research bottlenecks and support more standardized cannabis formulations for clinical development. The applications also illustrate the emerging commercial infrastructure around pharmaceutical-grade cannabis, even as broader federal and state markets remain governed by different regulatory systems.
Source: The Marijuana Herald
California–Paramount Merger Talks Stall Over Leak Dispute
California Attorney General Rob Bonta canceled a planned settlement meeting with Paramount Skydance over its proposed acquisition of Warner Bros. Discovery, accusing the company of leaking and misrepresenting confidential preliminary discussions. Paramount denied responsibility for the leak and said it remained prepared to participate in good-faith negotiations.
Bonta subsequently said talks could resume as soon as this week if the confidentiality dispute is resolved. He also indicated that an acceptable settlement would likely require structural remedies rather than operating promises, potentially including separate ownership of a significant portion of the combined company’s approximately 50 basic cable channels.
The proposed combination remains the subject of a multistate antitrust lawsuit involving California and other state attorneys general. The dispute affects major film studios, streaming services, broadcast operations and cable networks with deep economic ties to Los Angeles.
Why It Matters: Analysis: The remedies under discussion could materially change the economics and structure of one of Hollywood’s largest proposed consolidations. Whether negotiations restart will influence the future ownership of major entertainment assets as well as employment, production spending and corporate decision-making in Southern California.
Source: TheWrap
What We’re Watching
Over the next 24–72 hours, watch for publication and possible challenges to the DEA applications, additional filings or statements in the Aurora–Curaleaf contest, and signs that California and Paramount are returning to settlement negotiations. Any new takeover terms, formal Aurora board recommendation or agreement on structural media remedies would materially change the outlook for these stories.
